These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15055161)

  • 41. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
    Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Life-threatening graft-vs-host disease.
    Vargas-Díez E; García-Díez A; Marín A; Fernández-Herrera J
    Clin Dermatol; 2005; 23(3):285-300. PubMed ID: 15896544
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Graft-versus-host disease-like eruption preceding a nodal CD30+ lymphoma.
    Toonstra J; Lier JG; Steijlen PM; van de Kerkhof PC
    Eur J Dermatol; 2002; 12(4):364-6. PubMed ID: 12095883
    [No Abstract]   [Full Text] [Related]  

  • 46. Emerging drugs for acute graft-versus-host disease.
    Khaled Y; Reddy P; Krijanovski O
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute graft versus host disease following living donor liver transplantation: first Korean report.
    Cho EH; Suh KS; Yang SH; Lee HW; Cho JY; Cho YB; Yi NJ; Lee KU
    Hepatogastroenterology; 2007; 54(79):2120-2. PubMed ID: 18251173
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe graft versus host disease in a patient with globoid cell leukodystrophy following umbilical cord blood transplantation: resemblance to the twitcher mouse model.
    Ozen M; Uçkan D; Cetin M; Tezcan I; Tuncer M; Anlar B
    Turk J Pediatr; 2007; 49(3):304-6. PubMed ID: 17990586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Catastrophic graft-versus-host disease after lung transplantation proven by PCR-based chimerism analysis.
    Worel N; Bojic A; Binder M; Jaksch P; Mitterbauer G; Streubel B; Thalhammer F; Staudinger T; Laczika KF; Locker GJ
    Transpl Int; 2008 Nov; 21(11):1098-101. PubMed ID: 18764830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lung transplantation complicated by graft-versus-host disease and confounded by incidental transfusion-associated macrochimerism.
    Pavenski K; Kamel-Reid S; Wei C; Cserti-Gazdewich CM
    Transfusion; 2008 Oct; 48(10):2190-6. PubMed ID: 18631170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic graft-versus-hepatoblastoma effect.
    Inaba H; Handgretinger R; Furman W; Hale G; Leung W
    Pediatr Blood Cancer; 2006 Apr; 46(4):501-5. PubMed ID: 15806543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preventing transfusion-associated graft-versus-host disease.
    Smith DM; Kresie LA
    Transfusion; 2007 Jan; 47(1):173-4; author reply 174. PubMed ID: 17207248
    [No Abstract]   [Full Text] [Related]  

  • 56. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
    Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
    Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
    Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia.
    Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Ryu SG; Park CJ; Chi HS; Lee MS; Yun S; Lee JS; Lee KH
    Haematologica; 2005 Oct; 90(10):1380-8. PubMed ID: 16219575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation.
    Iori AP; Torelli GF; De Propris MS; Milano F; Pupella S; Gozzer M; Mancini F; Milani ML; Intoppa S; Cerretti R; Lucarelli B; Valle V; Malandruccolo L; Iannella E; Arleo E; Guarini A; Foà R
    Transplantation; 2008 Feb; 85(3):386-90. PubMed ID: 18322430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinicopathological features in patients with hepatic graft-versus-host disease.
    Chiba T; Yokosuka O; Goto S; Fukai K; Imazeki F; Kohno Y; Nishimura M; Saito Y; Saisho H
    Hepatogastroenterology; 2005; 52(66):1849-53. PubMed ID: 16334791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.